Horizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
|
|
- Ruth Malone
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Enobosarm (Ostarine) is intended to be used as first line therapy for the treatment of cachexia in patients with advanced non-small cell lung cancer (NSCLC) in combination with first line chemotherapy. If licensed, it would represent the first in a new class of drug for this patient group. Enobosarm is an oral, non-steroidal selective androgen receptor modulator (SARM). NSCLC accounts for approximately 80% of all lung cancers. Cachexia is common in patients with NSCLC and approximately 50% of patients with advanced NSCLC have severe muscle loss. Cachexia impairs quality of life and response to therapy, increasing the morbidity and mortality of cancer patients. The treatment approach for cachexia is multimodal and includes treatment of causes for decreased nutritional intake, evaluation of anti-neoplastic options to reduce the catabolic drive of cancer, nutritional therapy, use of corticosteroids and progestational agents, and non-drug treatment like nutritional counselling and physical training. Enobosarm is currently in two phase III clinical trials comparing its effect on physical function and lean body mass against placebo. This trial is expected to complete in second half of This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health., University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Cachexia in patients with non-small cell lung cancer (NSCLC): advanced (stage III or IV) first line; in combination with first line chemotherapy. TECHNOLOGY DESCRIPTION Enobosarm (Ostarine; GTx-024; MK-2866) is an oral, non-steroidal selective androgen receptor modulator (SARM). SARMs bind to the testosterone receptor and have both agonist and antagonist activities, depending on the specific targeted tissues. Enobosarm is intended for the prevention and treatment of cachexia in patients with stage III or IV NSCLC and is administered orally at 3mg/day in combination with first line chemotherapy (dose used in clinical trials). Enobosarm is also in phase II clinical trials for the treatment of muscular atrophy associated with ageing (sarcopenia). INNOVATION and/or ADVANTAGES Enobosarm is tissue selective and may potentially have positive anabolic effects with fewer side effects and limited toxicity compared to existing pharmacological agents. If licensed, enobosarm would represent the first in a new class of drug for this patient group, where options are currently limited. DEVELOPER GTx, Inc. AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND Cancer cachexia describes a multifactorial syndrome characterised by an ongoing loss of skeletal muscle, with or without loss of fat mass, in response to a malignant growth 1,2. The pathophysiology is characterised by a negative protein and energy balance which is driven by a variable combination of reduced food intake and abnormal metabolism 1. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to Improving Outcomes: A Strategy for Cancer (2011).
3 CLINICAL NEED and BURDEN OF DISEASE In the UK, lung cancer is the most common cause of cancer related death in men and women 3. In England and Wales, there were 35,406 new cases of lung cancer (ICD C33-34) in 2009 (approximately 48 cases per 100,000 population in the UK) 4 and around 29,977 deaths were registered in 2010 (approximately 38 deaths per 100,000 population in the UK) 3,5. About 90% of lung cancer mortality among men and 80% among women is attributable to smoking 6. NSCLC accounts for approximately 80% of all lung cancers; the main types being squamous cell carcinoma, adenocarcinoma and large cell carcinoma 7,8. Approximately 75% of newly diagnosed NSCLC patients have advanced (stage III or IV) disease in England and Wales (approximately 24,536 patients), which has a five-year survival rate of less than 1% 7. An estimated 25% of patients with NSCLC receive first line chemotherapy 7. Cachexia is common in patients with NSCLC 9. At diagnosis, approximately 50% of patients with advanced NSCLC have severe muscle loss 9. Cachexia is present in nearly 100% of treated cancer patients at death and accounts for at least 20% of deaths in neoplastic patients 2. Cachexia impairs quality of life and response to therapy, increasing morbidity and mortality of cancer patients 2. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Cetuximab for the treatment of advanced non-small cell lung cancer (ID9). Expected date of issue to be confirmed 10. NICE technology appraisal in development. Erlotinib and gefitinib for the second line treatment of non-small-cell lung cancer (review of TA162 and TA175) (ID620). Expected July NICE technology appraisal in development. Crizotinib for the treatment of previously treated non-small cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (ID499). Expected July NICE technology appraisal in development. Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-smallcell lung cancer (ID489). Expected June NICE technology appraisal. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258). June NICE technology appraisal. Erlotinib monotherapy for the maintenance treatment of nonsmall cell lung cancer (TA227). June NICE technology appraisal. Gefitinib for the first line treatment of locally advanced or metastatic non-small cell lung cancer (TA192). July NICE technology appraisal. Pemetrexed for the maintenance treatment of non-small cell lung cancer (TA190). June NICE technology appraisal. Pemetrexed for the first line treatment of non-small cell lung cancer (TA181). September NICE technology appraisal. Erlotinib for the treatment of non-small cell lung cancer (TA162). November NICE technology appraisal. Pemetrexed for the treatment of non-small cell lung cancer (TA124). August
4 NICE clinical guideline. The diagnosis and treatment of lung cancer (CG121). April NICE quality standard. Quality standard for lung cancer (QS17). March Other Guidance European Society for Medical Oncology (ESMO). Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up European Palliative Care Research Collaborative. Clinical practice guidelines on cancer cachexia in advanced cancer patients American College of Chest Physicians. Diagnosis and management of lung cancer: ACCP guidelines (2nd Edition) SIGN. Management of patients with lung cancer Cancer Services Collaborative Improvement Partnership. Lung cancer service improvement guide EXISTING COMPARATORS and TREATMENTS In patients with advanced NSCLC, the options for treating associated cachexia are limited. The approach is multimodal and includes 1 : treatment of secondary gastrointestinal symptoms and other causes for decreased nutritional intake. evaluation of anti-neoplastic options to reduce catabolic drive of cancer. nutritional treatment oral, enteral or parenteral nutrition therapy and use of supplements such as vitamins and minerals. non-drug treatment nutritional counselling or education, psychotherapeutic interventions and physical training. drug treatment short term use of corticosteroids (1-2 weeks) and progestational agents (megestrol and progestins). Other drugs like non-steroidal anti-inflammatory drugs, thalidomide and cytokine antagonists, cannabinioids, prokinetics and omega-3 fatty acids may be used to treat cancer cachexia; however their use is not recommended by the recent European guideline for the treatment of cachexia in patients with advanced cancer 1. Prophylactic interventions such as nutritional counselling and physical training are also thought to be beneficial in delaying or preventing the development of cachexia in cancer patients 1. EFFICACY and SAFETY Trial POWER1, NCT , G300504; enobosarm vs placebo, both in combination with first line platinum plus taxane chemotherapy; phase III. POWER2, NCT , G300505; enobosarm vs placebo, both in combination with first line platinum plus non-taxane chemotherapy; phase III. Sponsor GTx, Inc. GTx, Inc. Status Ongoing. Ongoing. Source of Trial registry 27, manufacturer 28. Trial registry 29, manufacturer 28. information Location USA. USA. Design Randomised, placebo-controlled. Randomised, placebo-controlled.
5 Participants Schedule Follow-up Primary outcome/s Secondary outcome/s Expected reporting date n=300 (planned); aged 30 years; NSCLC; stage III or IV; BMI 32; weight <300 lbs (136 kg); chemotherapy naïve; planned first line chemotherapy - platinum plus paclitaxel or docetaxel; not on treatment with testosterone, other androgenic compounds or medication to increase appetite or treat unintentional weight loss; Eastern Cooperative Oncology Group (ECOG) score 1; life expectancy >6 months; baseline stair climb time 30 seconds. Randomised to enobosarm 3mg or placebo, both once daily in combination with first line platinum plus taxane chemotherapy. Active treatment for 5 months, follow-up up to 30 months. Physical function assessed by stair climb test at day 84 and lean body mass assessed by whole body composition dexa scan at day 84. Responders analysis defined as 10% improvement in physical function and no loss in lean body mass. Durability of treatment effect on physical function and lean body mass; overall survival; healthcare resource utilisation; adherence to chemotherapy and dose intensity; total body weight; quality of life assessed using FAACT-12 a, FACIT fatigue scale b, patient reported outcomes measurement information system (PROMIS) physical functioning, PROMIS emotional distress-depression and EQ- 5D-5L. Study completion date reported as second half of n=300 (planned); aged 30 years; NSCLC; stage III or IV; BMI 32; weight <300 lbs (136 kg); chemotherapy naïve; planned first line chemotherapy - platinum plus gemcitabine, vinorelbine or pemetrexed; not on treatment with testosterone, other androgenic compounds or medication to increase appetite or treat unintentional weight loss; ECOG score 1; life expectancy >6 months; baseline stair climb time 30 seconds. Randomised to enobosarm 3mg or placebo, both once daily in combination with first line platinum plus non-taxane chemotherapy. Active treatment for 5 months, follow-up up to 30 months Physical function assessed by stair climb test at day 84 and lean body mass assessed by whole body composition dexa scan at day 84. Responders analysis defined as 10% improvement in physical function and no loss in lean body mass. Durability of treatment effect on physical function and lean body mass; overall survival; healthcare resource utilisation; adherence to chemotherapy and dose intensity; total body weight; quality of life using FAACT-12, FACIT fatigue scale, Patient reported outcomes measurement information system (PROMIS) physical functioning, PROMIS emotional distressdepression and EQ-5D-5L. Study completion date reported as second half of Trial Sponsor Status Source of information Location Design Participants NCT , G200502; enobosarm vs placebo; phase II. GTx, Inc. Complete but unpublished. Trial registry 30, manufacturer. USA and Canada. Randomised, placebo-controlled. n=150; males >45 years, females confirmed as postmenopausal; stage II, III or IV NSCLC, stage II, III or IV colorectal cancer, non-hodgkin s lymphoma, chronic lymphocytic leukaemia or stage III or IV breast cancer; experienced 2% body weight loss from highest reported weight in 6 months prior to screening; chemotherapy naïve or between cycles of chemotherapy; not on treatment with testosterone, other androgenic compounds or medication to increase appetite or treat unintentional a Functional Assessment of Anorexia/Cachexia Therapy (FAACT)-12 questionnaire measures general aspects of quality of life as well as specific anorexia/cachexia-related concerns. b Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue measures an individual s level of fatigue during their usual daily activities over the past week.
6 weight loss; ECOG score 1; life expectancy >6 months. Schedule Follow-up Primary outcome/s Secondary outcome/s Key results Adverse effects (AEs) Randomised to enobosarm 1mg, 3mg or placebo, all once daily. Active treatment for 16 weeks. Lean body mass. Body weight, muscle function and total body fat mass. For enobosarm 3mg, 1mg and placebo respectively: Median change in lean body mass (range, p vs baseline), 1.0kg (-4.8 to 11.5, p=0.046), 1.5kg (-2.1 to 12.6, p=0.001), not reported (p=0.88); mean improvement in stair climb (p vs baseline), 22% (p<0.001), 18% (p=0.001), not reported (p=0.15); median change in time required to climb 12 stairs (range, p vs baseline), -0.5s (5.1 to -31.0, p=0.007), -0.86s (5.6 to -12.7, p=0.002), -0.1s (14.5 to -4.6, p=0.26); median change in stair climb power (range, p vs baseline), watts (-77.7 to 93.1, p=0.001), 14.3 watts ( to 110.0, p=0.001), 2.2 watts ( to 56.4, p=0.10). There were no significant differences in the secondary endpoints of absolute change or percentage change in handgrip strength from baseline to day 113. For placebo, enobosarm 1mg and enobosarm 3mg groups respectively: all AEs, 88.5%, 88.7%, 90.7%; treatment related AEs, 15.4%, 13.2%, 27.8% and serious AEs, 32.7%, 26.4%, 27.8%. Common AEs reported included: anaemia, nausea, diarrhoea, malignant neoplasm progression, vomiting, weight loss, cough, dyspnoea and dehydration. ESTIMATED COST and IMPACT COST The cost of enobosarm is not yet known. IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Reduced symptoms or disability Other: No impact identified Impact on Services Increased use of existing services Decreased use of existing services Re-organisation of existing services Need for new services Other: None identified Impact on Costs Increased drug treatment costs Reduced drug treatment costs Other increase in costs: Other reduction in costs: Other: None identified
7 Other Issues Clinical uncertainty or other research question identified: It is not clear that the evidence base is being developed in the patients that have cachexia at presentation or develop it as part of the terminal phase of the illness. REFERENCES None identified 1 Radbruch L, Elsner F, Trottenberg P et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: Department of Palliative Medicinen/ European Palliative Care Research Collaborative, Patient.co.uk. Cachexia. Accessed 14 September Cancer research UK. Lung cancer mortality statistics. Accessed 14 September Cancer Research UK. Lung cancer - UK incidence statistics. Accessed 14 September Office for National Statistics. Mortality statistics: Deaths registered in 2010 (Series DR) Table Scottish Intercollegiate Guidelines Network. Management of patients with lung cancer. National clinical guideline 80. Edinburgh: SIGN; February National Institute for Health and Clinical Excellence. Final scope for the appraisal of erlotinib monotherapy for the maintenance treatment of advanced or metastatic non-small cell lung cancer. London: NICE; November Cancer Research UK. Types of Lung Cancer. Accessed 14 September GTx Inc. enobosarm (Ostarine ; GTx-024). Accessed 14 September National Institute for Health and Clinical Excellence. Cetuximab for the treatment of advanced non-small cell lung cancer (ID 9). Technology appraisal in development. Publication date not yet confirmed. 11 National Institute for Health and Clinical Excellence. Erlotinib and gefitinib for the second line treatment of non-small-cell lung cancer (review of TA162 and TA175). Technology appraisal in development. Expected July National Institute for Health and Clinical Excellence. Crizotinib for the treatment of previously treated non-small cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. Technology appraisal in development. Expected July National Institute for Health and Clinical Excellence. Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer. Technology appraisal in development. Expected June National Institute for Health and Clinical Excellence. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. Technology appraisal TA258. London: NICE; June National Institute for Health and Clinical Excellence. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer. Technology appraisal TA227. London: NICE; June National Institute for Health and Clinical Excellence. Gefitinib for the first line treatment of locally advanced or metastatic non-small cell lung cancer. Technology appraisal TA192. London: NICE; July National Institute for Health and Clinical Excellence. Pemetrexed for the maintenance treatment of non-small cell lung cancer. Technology appraisal TA190. London: NICE; June National Institute for Health and Clinical Excellence. Pemetrexed for the first line treatment of non-small cell lung cancer. Technology appraisal TA181. London: NICE; September National Institute for Health and Clinical Excellence. Erlotinib for the treatment of non-small cell lung cancer. Technology appraisal TA162. London: NICE; November National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small cell lung cancer. Technology appraisal TA124. London: NICE; August 2007.
8 21 National Institute for Health and Clinical Excellence. The diagnosis and treatment of lung cancer. Clinical guideline CG121. London: NICE; April National Institute for Health and Clinical Excellence. Quality standard for lung cancer. Quality standard. QS17. London: NICE; March European Society for Medical Oncology. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21(5):v116- v Radbruch L, Elsner F, Trottenberg P et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicinen/ European Palliative Care Research Collaborative; American College of Chest Physicians. Diagnosis and management of lung cancer: ACCP Evidence-based clinical practice guidelines (2nd Edition). Chest 2007;132(3): Cancer Services Collaborative Improvement partnership. Lung cancer service improvement guide. October Accessed 14 September ClinicalTrials.gov. Phase III study of the effect of GTx-024 on muscle wasting in patients with nonsmall cell lung cancer (NSCLC). Accessed 14 September GTx Inc. News Releases: GTx provides corporate update and reports 2011 financial results. Accessed 14 September ClinicalTrials.gov. Effect of GTx-024 on muscle wasting in patients with non-small cell lung cancer (NSCLC) on first line platinum. Accessed 14 September ClinicalTrials.gov. Study of GTx-024 on muscle wasting (cachexia) cancer. Accessed 14 September 2012.
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationTechnology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationTechnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402
Pemetrexed ed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed ed and cisplatin Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta402 NICE
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationThe Challenge of Cancer Cachexia
The Challenge of Cancer Cachexia Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Director, Solid Tumor Therapeutics Program Duke Cancer Institute Disclosures Advisory Board/Consultant:
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationSingle Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell lung cancer
Single Technology Appraisal (STA) Anamorelin for treating cachexia and anorexia in people with non-small-cell Response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
More informationTwo late stage clinical programs
Safe harbor This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationTechnology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer Technology appraisal guidance Published: 23 April 2014 nice.org.uk/guidance/ta310
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationSingle Technology Appraisal (STA)
Single Technology Appraisal (STA) Durvalumab for maintenance treatment of locally advanced unresectable non-small cell lung cancer that has not progressed after platinum-based chemoradiation therapy Response
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395
Ceritinib for previously treated anaplastic lymphoma kinase positive non- small-cell lung cancer Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta5 NICE 2018. All rights reserved.
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationLead team presentation:
Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta422
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta422 NICE 2018.
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThe pcodr review also provided contextual information on ALK mutation testing.
only approximately 4% of NSCLC patients are expected to have the ALK mutation. perc further discussed these estimates in the context of the feasibility of implementing a funding recommendation for crizotinib.
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Technology Summary. Temozolomide (Temodal) for advanced metastatic melanoma. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Temozolomide (Temodal) for advanced metastatic melanoma April 2007 This technology summary is based on information available at the
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationPembrolizumab in combination with epacadostat for unresectable or metastatic melanoma
NIHR Innovation Observatory Evidence Briefing: January 2018 Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma NIHRIO (HSRIC) ID: 7812 NICE ID: 9396 LAY SUMMARY Melanoma
More informationAR101 peanut allergy immunotherapy for adult and paediatric patients
AR101 peanut allergy immunotherapy for adult and paediatric patients NIHRIO (HSRIC) ID: 11815 NIHR Innovation Observatory Evidence Briefing: May 2017 NICE ID: 8773 LAY SUMMARY Food allergy occurs when
More informationTechnology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE
More informationRe-Submission. Scottish Medicines Consortium. erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche. 5 May 2006
Scottish Medicines Consortium Re-Submission erlotinib, 100 and 150mg film-coated tablets (Tarceva ) No. 220/05 Roche 5 May 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationTechnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374
Erlotinib and gefitinib for treating non- small-cell lung cancer that has progressed after prior chemotherapy Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 NICE 2017.
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta406
Crizotinib for untreated anaplastic lymphoma kinase-positive e advanced non- small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta406 NICE 2018. All
More informationA new era of therapeutics for cancer cachexia. Cachexia is a continuum with 3 stages of clinical relevance
A new era of therapeutics for cancer cachexia I. Depletion of Reserves II. Limitation of food intake III. Catabolic Drivers IV. Impact and outcomes Vickie Baracos PhD Professor and Alberta Cancer Foundation
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationTechnology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192
Gefitinib for the first-line treatment of locally advanced or metastatic non-small- cell lung cancer Technology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192 NICE 2018. All rights
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationNivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer first line
NIHR Innovation Observatory Evidence Briefing: September 2017 Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer first line NIHRIO (HSRIC) ID: 12568
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationTicagrelor (Brilique) for peripheral arterial disease
July 2016 Horizon Scanning Research & Intelligence Centre Ticagrelor (Brilique) for peripheral arterial disease LAY SUMMARY This briefing is based on information available at the time of research and a
More informationDarbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes
NIHR Innovation Observatory Evidence Briefing: August 2017 Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes NIHRIO (HSRIC) ID: 13763
More informationTechnology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 NICE 2018. All rights
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationTwo late stage clinical programs
Safe harbor This presentation and our remarks based upon it, including responses to questions made during and following the presentation, may include forward-looking statements. Such statements are subject
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 NICE 2017. All rights reserved.
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationPembroluzimab (Keytruda ) for triple negative breast cancer
Pembroluzimab (Keytruda ) for triple negative breast cancer NIHRIO (HSRIC) ID: 11227 NIHR Innovation Observatory Evidence Briefing: April 2017 NICE ID:9119 LAY SUMMARY Breast cancer is the most common
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationSetmelanotide for pro-opiomelanocortin deficiency obesity
NIHR Innovation Observatory Evidence Briefing: September 2017 Setmelanotide for pro-opiomelanocortin deficiency obesity NIHRIO (HSRIC) ID: 8496 NICE ID: 9505 LAY SUMMARY Body fat and food intake are regulated
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationEli Lilly and Company Ltd
www.lilly.co.uk Eli Lilly and Company Limited Lilly House Priestley Road Basingstoke Hampshire RG24 9NL Medical and Product Information: +44 (0) 1256 315999 28 February 2007 Mr Christopher Feinmann Technology
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationFinal PROTOCOL. This report was commissioned by the NIHR HTA Programme as project number 12/49/01. Completed 28 th March 2013 DOES NOT CONTAIN CIC/AIC
Final PROTOCOL Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175) This report was commissioned
More informationBenefit Risk Analysis Of Decision-Making: Oncology
Benefit Risk Analysis Of Decision-Making: Oncology G.K. Raju, Ph.D. December 13 th 2016 Outline Background Approach Application to Oncology Non-Small Cell Lung Cancer Learnings & Ongoing Work Acknowledgements
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information